Prenetics boosts liquidity to $171.1M with $70M sale and names longevity expert to board
Prenetics sold its 35% equity interest in Insighta to Tencent for $70 million in cash, lifting total adjusted liquidity to $171.1 million with zero debt to support IM8’s global expansion. The company also appointed longevity expert Dr. Darshan Shah to its board and key committees to bolster scientific and commercial leadership.
1. Prenetics Sells Insighta Stake for $70M
Prenetics completed the sale of its 35% equity interest in Insighta to Tencent for $70 million in cash. The transaction increases total adjusted liquidity to $171.1 million, leaves the company debt-free and earmarks proceeds to accelerate the IM8 brand’s rollout in over 30 countries after surpassing $100 million in annualized recurring revenue.
2. Longevity Expert Dr. Darshan Shah Joins Board
Effective February 16, Dr. Darshan Shah, a Mayo Clinic–trained surgeon with over 20,000 procedures and founder of Next Health, was appointed as an independent director. He will serve on the Audit, Compensation and Nominating & Corporate Governance Committees, bringing deep clinical trial, product formulation and brand-building experience to support IM8’s science-backed growth strategy.